| Douglas Alex Deboise, MD | |
|
301 S 70th St, Suite 200, Lincoln, NE 68510-2469 | |
| (402) 483-7641 | |
| (402) 483-7641 |
| Full Name | Douglas Alex Deboise |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 47 Years |
| Location | 301 S 70th St, Lincoln, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851408637 | NPI | - | NPPES |
| 47082083213 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 16816 (Nebraska) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Obhg Nebraska Pc | 0244514487 | 3 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
A team of researchers in the University of Arizona's College of Pharmacy has discovered a molecular pathway that could be key to creating new therapeutics that would slow or even reverse the progression of end-stage liver disease.
The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).
Reducing sugar intake by the equivalent of one can of soda per day and increasing fiber intake by the amount equivalent to one half cup of beans per day appears to improve risk factors associated with type 2 diabetes in Latino adolescents, according to a report in the April issue of Archives of Pediatrics & Adolescent Medicine.
› Verified 9 days ago
| Entity Name | Alegent Creighton Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548287907 PECOS PAC ID: 1951210418 Enrollment ID: O20040407001314 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
A team of researchers in the University of Arizona's College of Pharmacy has discovered a molecular pathway that could be key to creating new therapeutics that would slow or even reverse the progression of end-stage liver disease.
The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).
Reducing sugar intake by the equivalent of one can of soda per day and increasing fiber intake by the amount equivalent to one half cup of beans per day appears to improve risk factors associated with type 2 diabetes in Latino adolescents, according to a report in the April issue of Archives of Pediatrics & Adolescent Medicine.
› Verified 9 days ago
| Entity Name | Obhg Nebraska Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386192896 PECOS PAC ID: 0244514487 Enrollment ID: O20170307000779 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
A team of researchers in the University of Arizona's College of Pharmacy has discovered a molecular pathway that could be key to creating new therapeutics that would slow or even reverse the progression of end-stage liver disease.
The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).
Reducing sugar intake by the equivalent of one can of soda per day and increasing fiber intake by the amount equivalent to one half cup of beans per day appears to improve risk factors associated with type 2 diabetes in Latino adolescents, according to a report in the April issue of Archives of Pediatrics & Adolescent Medicine.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Douglas Alex Deboise, MD 301 S 70th St, Suite 200, Lincoln, NE 68510-2469 Ph: (402) 483-7641 | Douglas Alex Deboise, MD 301 S 70th St, Suite 200, Lincoln, NE 68510-2469 Ph: (402) 483-7641 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed for review Genentech's new drug application (NDA) for vismodegib for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.
A team of researchers in the University of Arizona's College of Pharmacy has discovered a molecular pathway that could be key to creating new therapeutics that would slow or even reverse the progression of end-stage liver disease.
The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).
Reducing sugar intake by the equivalent of one can of soda per day and increasing fiber intake by the amount equivalent to one half cup of beans per day appears to improve risk factors associated with type 2 diabetes in Latino adolescents, according to a report in the April issue of Archives of Pediatrics & Adolescent Medicine.
› Verified 9 days ago
Todd D Martin, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6050 Village Dr, Lincoln, NE 68516 Phone: 402-421-8581 Fax: 402-421-8594 | |
Meggan L Linck, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1001 S 70th St Ste 220, Lincoln, NE 68510 Phone: 402-486-4800 Fax: 402-853-5465 | |
Dr. Yvonne K Davenport, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 9110 Andermatt Dr Ste 2, Lincoln, NE 68526 Phone: 402-483-7641 Fax: 402-483-0527 | |
Dr. Torri Marie Janecek, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5055 A St Ste 200, Lincoln, NE 68510 Phone: 402-483-8630 Fax: 402-483-8578 | |
Sharon L Hier-duffin, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 7001 A St, Ste 200, Lincoln, NE 68510 Phone: 402-488-4022 Fax: 402-488-4113 | |
Maureen Patrice Malee, MD PHD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1500 S 48th St, Suite 712, Lincoln, NE 68506 Phone: 402-483-8485 Fax: 402-483-8486 | |
Dr. Robert Thomas Byington, MD OBGYN Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1530s 70th St 100, Lincoln, NE 68506 Phone: 402-488-2348 Fax: 402-488-2463 |